Clarius Group LLC’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,000
| Closed | -$91.2K | – | 463 |
|
|
2025
Q2 | $91.2K | Hold |
10,000
| – | – | 0.01% | 469 |
|
|
2025
Q1 | $79.5K | Hold |
10,000
| – | – | 0.01% | 473 |
|
|
2024
Q4 | $54.3K | Hold |
10,000
| – | – | ﹤0.01% | 447 |
|
|
2024
Q3 | $72.2K | Hold |
10,000
| – | – | 0.01% | 447 |
|
|
2024
Q2 | $109K | Hold |
10,000
| – | – | 0.01% | 435 |
|
|
2024
Q1 | $187K | Hold |
10,000
| – | – | 0.01% | 462 |
|
|
2023
Q4 | $217K | Sell |
10,000
-994
| -9% | -$19.7K | 0.02% | 435 |
|
|
2023
Q3 | $226K | Buy |
10,994
+240
| +2% | +$6.93K | 0.02% | 408 |
|
|
2023
Q2 | $506K | Hold |
10,754
| – | – | 0.04% | 258 |
|
|
2023
Q1 | $451K | Hold |
10,754
| – | – | 0.04% | 282 |
|
|
2022
Q4 | $410K | Buy |
10,754
+28
| +0.3% | +$1.07K | 0.04% | 292 |
|
|
2022
Q3 | $420K | Buy |
10,726
+549
| +5% | +$21.2K | 0.04% | 255 |
|
|
2022
Q2 | $329K | Buy |
+10,177
| New | +$341K | 0.03% | 316 |
|
|
2020
Q4 | – | Sell |
-35,500
| Closed | -$2.17M | – | 357 |
|
|
2020
Q3 | $2.17M | Hold |
35,500
| – | – | 0.28% | 42 |
|
|
2020
Q2 | $1.48M | Hold |
35,500
| – | – | 0.21% | 57 |
|
|
2020
Q1 | $1.02M | Hold |
35,500
| – | – | 0.19% | 63 |
|
|
2019
Q4 | $2.66M | Buy |
+35,500
| New | +$4.37M | 0.42% | 31 |
|
|
2017
Q4 | – | Sell |
-129,068
| Closed | -$8.04M | – | 72 |
|
|
2017
Q3 | $8.04M | Sell |
129,068
-20,000
| -13% | -$1.57M | 3.39% | 4 |
|
|
2017
Q2 | $11.9M | Hold |
149,068
| – | – | 4.89% | 4 |
|
|
2017
Q1 | $10.6M | Hold |
149,068
| – | – | 4.37% | 4 |
|
|
2016
Q4 | $7.91M | Hold |
149,068
| – | – | 3.35% | 5 |
|
|
2016
Q3 | $6.87M | Hold |
149,068
| – | – | 3.2% | 4 |
|
|
2016
Q2 | $4.49M | Buy |
149,068
+38,118
| +34% | +$1.27M | 2.39% | 7 |
|
|
2016
Q1 | $3.56M | Buy |
+110,950
| New | +$3.91M | 1.97% | 8 |
|
Other funds holding SAGE
IA
HNB
Clarius Group LLC's SAGE Position: Q3 2025 in Review
Clarius Group LLC sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 10,000 shares — an estimated $91.2K sold.
Clarius Group LLC first reported a position in SAGE in Q1 2016 and held it in 24 quarters. The position peaked at $11.9M in Q2 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Clarius Group LLC reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Clarius Group LLC sold 10,000 Sage Therapeutics shares in Q3 2025, an estimated $91.2K.
- Clarius Group LLC first reported a position in Sage Therapeutics in Q1 2016 and held it in 24 quarters.
- Clarius Group LLC's Sage Therapeutics position peaked at $11.9M in Q2 2017.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Clarius Group LLC's 13F filing for Q3 2025, filed 14 Oct 2025.